Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
| Autor: | Eadie, Laura N., Lagonik, Elias, Page, Elyse C., Schutz, Caitlin E., Heatley, Susan L., McClure, Barbara J., Forgione, Michelle O., Yeung, David T., Hughes, Timothy P., White, Deborah L. |
|---|---|
| Zdroj: | In Blood 29 August 2024 144(9):1022-1026 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|